This research aims to test a medicine called Fosmanogepix to treat severe fungal infections called candidemia or invasive candidiasis. These infections are caused by yeast, a type of fungus, and can be very serious. The study includes patients who have these infections. In the study, two-thirds of participants will receive Fosmanogepix through an IV, which is a way to deliver medicine directly into a vein. The other third will get standard treatments with another medicine through an IV. Participants may also take tablets or capsules by mouth at home or the clinic. The goal is to see if Fosmanogepix works as well as the standard treatment.

• You may need to be in the study for up to 6 weeks, with a follow-up 6 weeks after treatment.
• Participants will be randomly assigned to different treatments, with daily visits at first.
• The study will compare the new treatment to the standard one, with risks and benefits explained.